<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368081</url>
  </required_header>
  <id_info>
    <org_study_id>1245.52</org_study_id>
    <nct_id>NCT01368081</nct_id>
  </id_info>
  <brief_title>Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the long-term safety and efficacy of BI 10773
      given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2
      diabetes mellitus with insufficient glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Drug Related Adverse Events</measure>
    <time_frame>After the first drug intake until 7 days after the last treatment administration, up to 383 days</time_frame>
    <description>Number of Patients With Drug Related Adverse Events after the first drug intake until 7 days after the last treatment administration, up to 383 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in HbA1c after 52 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Hypoglycaemic Adverse Events</measure>
    <time_frame>After the first drug intake until 7 days after the last treatment administration, up to 383 days</time_frame>
    <description>Number of patients with confirmed hypoglycaemic adverse events</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1162</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 low dose tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 high dose tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin tablets 500-2250 mg a day (twice or three times per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin tablets 500-2250 mg a day (twice or three times per day)</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 low dose tablet once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (low dose)</intervention_name>
    <description>Placebo tablets once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 high dose tablet once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (high dose)</intervention_name>
    <description>Placebo tablets once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  .Diagnosis of type 2 diabetes mellitus prior to informed consent

          -  Male and female patients, on diet and exercise regimen, who are pre-treated with one
             of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide,
             Alpha-glucosidase inhibitor (a-GI), dipeptidyl peptidase-IV (DPP-IV) inhibitor or
             thiazolidinedione

          -  glycosylated haemoglobin (HbA1c) at Visit 1: &gt;=7.0 to =&lt;10.0% (national
             glycohemoglobin standardization program)

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dL (&gt;13.3 mmol/L)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.52.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adachi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aki-gun, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annaka, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atami, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beppu, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fujisawa, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hadano, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamamatsu, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Imabari, Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iruma,Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isehara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isesaki, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izumisano,Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura,Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanazawa, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanoya, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kashiwa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasugai, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-adachi-gun, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyushu, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kodaira, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshigaya, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuki, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kure, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maebashi, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maebashi, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsuyama, Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meguro-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyazaki, Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyazaki, Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naha, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naha, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjyo, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita, Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okawa, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka,Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaki, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ota-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saga, Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagamihara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagamihara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakado, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saku, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Setagaya-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimajiri-gun, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimajiri-gun, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku. Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takatsuki, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokorozawa, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokorozawa, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomigusuku, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomigusuku, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uji, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uruma, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.52.084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulfonylurea: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
        </group>
        <group group_id="P2">
          <title>Sulfonylurea: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
        </group>
        <group group_id="P3">
          <title>Sulfonylurea: Metformin</title>
          <description>250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea</description>
        </group>
        <group group_id="P4">
          <title>Biguanide: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
        </group>
        <group group_id="P5">
          <title>Biguanide: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
        </group>
        <group group_id="P6">
          <title>Thiazolidinedione: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
        </group>
        <group group_id="P7">
          <title>Thiazolidinedione: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
        </group>
        <group group_id="P8">
          <title>Alpha Glucosidase Inhibitor: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
        </group>
        <group group_id="P9">
          <title>Alpha Glucosidase Inhibitor: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
        </group>
        <group group_id="P10">
          <title>DPP−IV Inhibitor: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of dipeptidyl peptidase IV (DPP−IV) inhibitor</description>
        </group>
        <group group_id="P11">
          <title>DPP−IV Inhibitor: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of dipeptidyl peptidase IV (DPP−IV) inhibitor</description>
        </group>
        <group group_id="P12">
          <title>Glinide: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
        </group>
        <group group_id="P13">
          <title>Glinide: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="137"/>
                <participants group_id="P7" count="136"/>
                <participants group_id="P8" count="69"/>
                <participants group_id="P9" count="70"/>
                <participants group_id="P10" count="68"/>
                <participants group_id="P11" count="71"/>
                <participants group_id="P12" count="70"/>
                <participants group_id="P13" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="63"/>
                <participants group_id="P6" count="127"/>
                <participants group_id="P7" count="124"/>
                <participants group_id="P8" count="62"/>
                <participants group_id="P9" count="62"/>
                <participants group_id="P10" count="58"/>
                <participants group_id="P11" count="62"/>
                <participants group_id="P12" count="67"/>
                <participants group_id="P13" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulfonylurea: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
        </group>
        <group group_id="B2">
          <title>Sulfonylurea: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
        </group>
        <group group_id="B3">
          <title>Sulfonylurea: Metformin</title>
          <description>250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea</description>
        </group>
        <group group_id="B4">
          <title>Biguanide: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
        </group>
        <group group_id="B5">
          <title>Biguanide: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
        </group>
        <group group_id="B6">
          <title>Thiazolidinedione: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
        </group>
        <group group_id="B7">
          <title>Thiazolidinedione: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
        </group>
        <group group_id="B8">
          <title>Alpha Glucosidase Inhibitor: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
        </group>
        <group group_id="B9">
          <title>Alpha Glucosidase Inhibitor: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
        </group>
        <group group_id="B10">
          <title>DPP−IV Inhibitor: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
        </group>
        <group group_id="B11">
          <title>DPP−IV Inhibitor: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
        </group>
        <group group_id="B12">
          <title>Glinide: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
        </group>
        <group group_id="B13">
          <title>Glinide: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="137"/>
            <count group_id="B7" value="136"/>
            <count group_id="B8" value="69"/>
            <count group_id="B9" value="70"/>
            <count group_id="B10" value="68"/>
            <count group_id="B11" value="71"/>
            <count group_id="B12" value="70"/>
            <count group_id="B13" value="70"/>
            <count group_id="B14" value="1160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.9"/>
                    <measurement group_id="B2" value="61.8" spread="9.6"/>
                    <measurement group_id="B3" value="60.0" spread="10.2"/>
                    <measurement group_id="B4" value="56.9" spread="9.5"/>
                    <measurement group_id="B5" value="57.3" spread="11.4"/>
                    <measurement group_id="B6" value="60.4" spread="10.1"/>
                    <measurement group_id="B7" value="59.7" spread="9.9"/>
                    <measurement group_id="B8" value="63.5" spread="8.8"/>
                    <measurement group_id="B9" value="61.9" spread="11.7"/>
                    <measurement group_id="B10" value="63.3" spread="9.9"/>
                    <measurement group_id="B11" value="59.1" spread="10.3"/>
                    <measurement group_id="B12" value="59.2" spread="12.1"/>
                    <measurement group_id="B13" value="57.7" spread="11.8"/>
                    <measurement group_id="B14" value="60.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="27"/>
                    <measurement group_id="B11" value="23"/>
                    <measurement group_id="B12" value="23"/>
                    <measurement group_id="B13" value="13"/>
                    <measurement group_id="B14" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="114"/>
                    <measurement group_id="B7" value="102"/>
                    <measurement group_id="B8" value="51"/>
                    <measurement group_id="B9" value="52"/>
                    <measurement group_id="B10" value="41"/>
                    <measurement group_id="B11" value="48"/>
                    <measurement group_id="B12" value="47"/>
                    <measurement group_id="B13" value="57"/>
                    <measurement group_id="B14" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c</title>
        <description>Change from baseline in HbA1c after 52 weeks of treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Sulfonylurea: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Sulfonylurea: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O3">
            <title>Sulfonylurea: Metformin</title>
            <description>250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O4">
            <title>Biguanide: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
          </group>
          <group group_id="O5">
            <title>Biguanide: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
          </group>
          <group group_id="O6">
            <title>Thiazolidinedione: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
          </group>
          <group group_id="O7">
            <title>Thiazolidinedione: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
          </group>
          <group group_id="O8">
            <title>Alpha Glucosidase Inhibitor: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
          </group>
          <group group_id="O9">
            <title>Alpha Glucosidase Inhibitor: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
          </group>
          <group group_id="O10">
            <title>DPP−IV Inhibitor: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
          </group>
          <group group_id="O11">
            <title>DPP−IV Inhibitor: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
          </group>
          <group group_id="O12">
            <title>Glinide: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
          </group>
          <group group_id="O13">
            <title>Glinide: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c</title>
          <description>Change from baseline in HbA1c after 52 weeks of treatment</description>
          <population>Full analysis set</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="136"/>
                <count group_id="O8" value="69"/>
                <count group_id="O9" value="70"/>
                <count group_id="O10" value="68"/>
                <count group_id="O11" value="71"/>
                <count group_id="O12" value="70"/>
                <count group_id="O13" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.05"/>
                    <measurement group_id="O2" value="-0.96" spread="0.05"/>
                    <measurement group_id="O3" value="-0.97" spread="0.08"/>
                    <measurement group_id="O4" value="-0.81" spread="0.06"/>
                    <measurement group_id="O5" value="-0.98" spread="0.06"/>
                    <measurement group_id="O6" value="-0.90" spread="0.05"/>
                    <measurement group_id="O7" value="-0.96" spread="0.05"/>
                    <measurement group_id="O8" value="-0.87" spread="0.06"/>
                    <measurement group_id="O9" value="-0.77" spread="0.06"/>
                    <measurement group_id="O10" value="-1.00" spread="0.06"/>
                    <measurement group_id="O11" value="-0.83" spread="0.06"/>
                    <measurement group_id="O12" value="-0.98" spread="0.08"/>
                    <measurement group_id="O13" value="-0.98" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Drug Related Adverse Events</title>
        <description>Number of Patients With Drug Related Adverse Events after the first drug intake until 7 days after the last treatment administration, up to 383 days</description>
        <time_frame>After the first drug intake until 7 days after the last treatment administration, up to 383 days</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Sulfonylurea: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Sulfonylurea: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O3">
            <title>Sulfonylurea: Metformin</title>
            <description>250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O4">
            <title>Biguanide: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
          </group>
          <group group_id="O5">
            <title>Biguanide: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
          </group>
          <group group_id="O6">
            <title>Thiazolidinedione: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
          </group>
          <group group_id="O7">
            <title>Thiazolidinedione: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
          </group>
          <group group_id="O8">
            <title>Alpha Glucosidase Inhibitor: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
          </group>
          <group group_id="O9">
            <title>Alpha Glucosidase Inhibitor: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
          </group>
          <group group_id="O10">
            <title>DPP−IV Inhibitor: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
          </group>
          <group group_id="O11">
            <title>DPP−IV Inhibitor: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
          </group>
          <group group_id="O12">
            <title>Glinide: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
          </group>
          <group group_id="O13">
            <title>Glinide: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug Related Adverse Events</title>
          <description>Number of Patients With Drug Related Adverse Events after the first drug intake until 7 days after the last treatment administration, up to 383 days</description>
          <population>Treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="136"/>
                <count group_id="O8" value="69"/>
                <count group_id="O9" value="70"/>
                <count group_id="O10" value="68"/>
                <count group_id="O11" value="71"/>
                <count group_id="O12" value="70"/>
                <count group_id="O13" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="9"/>
                    <measurement group_id="O11" value="18"/>
                    <measurement group_id="O12" value="9"/>
                    <measurement group_id="O13" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Hypoglycaemic Adverse Events</title>
        <description>Number of patients with confirmed hypoglycaemic adverse events</description>
        <time_frame>After the first drug intake until 7 days after the last treatment administration, up to 383 days</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Sulfonylurea: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Sulfonylurea: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O3">
            <title>Sulfonylurea: Metformin</title>
            <description>250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea</description>
          </group>
          <group group_id="O4">
            <title>Biguanide: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
          </group>
          <group group_id="O5">
            <title>Biguanide: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
          </group>
          <group group_id="O6">
            <title>Thiazolidinedione: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
          </group>
          <group group_id="O7">
            <title>Thiazolidinedione: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
          </group>
          <group group_id="O8">
            <title>Alpha Glucosidase Inhibitor: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
          </group>
          <group group_id="O9">
            <title>Alpha Glucosidase Inhibitor: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha glucosidase inhibitor</description>
          </group>
          <group group_id="O10">
            <title>DPP−IV Inhibitor: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
          </group>
          <group group_id="O11">
            <title>DPP−IV Inhibitor: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP−IV inhibitor</description>
          </group>
          <group group_id="O12">
            <title>Glinide: Empa 10mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
          </group>
          <group group_id="O13">
            <title>Glinide: Empa 25mg</title>
            <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypoglycaemic Adverse Events</title>
          <description>Number of patients with confirmed hypoglycaemic adverse events</description>
          <population>Treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="137"/>
                <count group_id="O7" value="136"/>
                <count group_id="O8" value="69"/>
                <count group_id="O9" value="70"/>
                <count group_id="O10" value="68"/>
                <count group_id="O11" value="71"/>
                <count group_id="O12" value="70"/>
                <count group_id="O13" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After the first drug intake until 7 days after the last treatment administration, up to 383 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulfonylurea: Empa 10mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
        </group>
        <group group_id="E2">
          <title>Sulfonylurea: Empa 25mg</title>
          <description>One tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Sulfonylurea</description>
        </group>
        <group group_id="E3">
          <title>Sulfonylurea: Metformin</title>
          <description>250mg tablet of metformin twice daily for 52 weeks, as an open-label treatment, for patients with background treatment of Sulfonylurea</description>
        </group>
        <group group_id="E4">
          <title>Biguanide: Empa 10mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
        </group>
        <group group_id="E5">
          <title>Biguanide: Empa 25mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Biguanide</description>
        </group>
        <group group_id="E6">
          <title>Thiazolidinedione: Empa 10mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
        </group>
        <group group_id="E7">
          <title>Thiazolidinedione: Empa 25mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Thiazolidinedione</description>
        </group>
        <group group_id="E8">
          <title>Alpha-GI: Empa 10mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha-GI</description>
        </group>
        <group group_id="E9">
          <title>Alpha-GI: Empa 25mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Alpha-GI</description>
        </group>
        <group group_id="E10">
          <title>DPP-4 Inhibitor: Empa 10mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP-4 inhibitor</description>
        </group>
        <group group_id="E11">
          <title>DPP-4 Inhibitor: Empa 25mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of DPP-4 inhibitor</description>
        </group>
        <group group_id="E12">
          <title>Glinide: Empa 10mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
        </group>
        <group group_id="E13">
          <title>Glinide: Empa 25mg</title>
          <description>tablet of empagliflozin (empa) once daily for 52 weeks as an add-on therapy for patients with a background treatment of Glinide</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Leukoplakia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="77" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="74" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="40" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="34" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="37" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="36" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="30" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="38" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="17" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

